Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto
US-2024248090-A1 · Jul 25, 2024 · US
US9481713B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9481713-B2 |
| Application number | US-201414263147-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2014 |
| Priority date | Jul 16, 2010 |
| Publication date | Nov 1, 2016 |
| Grant date | Nov 1, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides.
Opening claim text (preview).
What is claimed is: 1. A method for regenerating a dental tissue in a patient in need thereof comprising administering to the dental tissue of said patient an effective amount of a self-assembling peptide, wherein the self-assembling peptide comprises: a. a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and wherein said domain self-assembles into a macroscopic structure when present in unmodified form, wherein the first amino acid domain has the sequence VEVKVEVKV (SEQ ID NO: 2) or VEVKVEVKVEVK (SEQ ID NO: 3); and b. a second amino acid domain that does not mediate self-assembly in isolated form, wherein the second amino acid domain comprises a biologically active motif. 2. The method of claim 1 , wherein the dental tissue is periodontal ligament tissue. 3. The method of claim 1 , wherein the biologically active motif is a laminin cell adhesion motif. 4. The method of claim 1 , wherein the second amino acid domain comprises a sequence selected from the group consisting of PDGSR (SEQ ID NO: 4), YIGSR (SEQ ID NO: 5), IKVAV (SEQ ID NO: 6), LRE (SEQ ID NO: 7), RNIAEIIKDI (SEQ ID NO:8), RYVVLPR (SEQ ID NO: 9), LGTIPG (SEQ ID NO: 10), PVGLIG (SEQ ID NO: 19) and GPVGLIG (SEQ ID NO: 12). 5. The method of claim 1 , wherein the second amino acid domain comprises an RGD peptide. 6. The method of claim 1 , wherein the second amino acid domain comprises a matrix metalloproteinase cleavable substrate. 7. The method of claim 6 , wherein the second amino acid domain comprises the sequence PVGLIG (SEQ ID NO: 19). 8. A method of treating periodontal disease in a patient in need thereof comprising administering to the periodontium of said patient an effective amount of a self-assembling peptide, wherein the self-assembling peptide comprises: a. a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and wherein said domain self-assembles into a macroscopic structure when present in unmodified form, wherein the first amino acid domain has the sequence VEVKVEVKV (SEQ ID NO: 2) or VEVKVEVKVEVK (SEQ ID NO: 3); and b. a second amino acid domain that does not mediate self-assembly in isolated form, wherein the second amino acid domain comprises a biologically active motif. 9. The method of claim 8 , wherein the method further comprises administering an effective amount of a solid biomaterial. 10. The method of claim 9 , wherein the biomaterial comprises calcium, phosphorous or a combination thereof. 11. The method of claim 9 , wherein the biomaterial comprises pores having a diameter from about 100 to about 500 microns.
characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells · CPC title
Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title
having 5 to 11 amino acids · CPC title
Dental/periodontal tissues · CPC title
Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.